Efficacy

Emgality (Galcanezumab) for Migraine Prevention

Emgality (galcanezumab) is a calcitonin gene-related peptide (CGRP) antagonist designed for the prevention of migraine in adults. Clinical trials have demonstrated its efficacy in reducing the frequency of migraine days in patients with episodic and chronic migraine. In these trials, patients treated with Emgality experienced a significant reduction in the number of monthly migraine days compared to those who received a placebo. The treatment was generally well-tolerated, and the most common adverse reactions reported were injection site reactions.

Long-Term Efficacy of Emgality

The long-term efficacy of Emgality has been supported by extension phases of pivotal trials, where the reduction in monthly migraine days was sustained over a period of up to 12 months. Patients who continued treatment with Emgality maintained a lower frequency of migraine days, suggesting that the benefits of the medication persist with ongoing use. This sustained efficacy is an important consideration for patients and healthcare providers when selecting a preventive treatment for migraines.

Ubrelvy (Ubrogepant) for Acute Migraine Treatment

Ubrelvy (ubrogepant) is an oral CGRP receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. Clinical studies have shown that Ubrelvy is effective in relieving migraine pain and the most bothersome symptom identified by the patient, such as nausea or light sensitivity, within two hours of taking the medication. The efficacy of Ubrelvy was evaluated in randomized controlled trials, where a higher percentage of patients achieved pain freedom and absence of their most bothersome symptom compared to placebo at two hours post-dose.

Considerations for Ubrelvy Use

Ubrelvy's efficacy in treating individual migraine attacks supports its use as an acute treatment option. It is important to note that Ubrelvy is not intended for the preventive treatment of migraine and should not be used for more than 15 days per month to avoid medication overuse headaches. The safety and effectiveness of Ubrelvy have been established in short-term studies, and its role in the long-term management of migraine requires further investigation. As with any medication, the decision to use Ubrelvy should be made in consultation with a healthcare provider, taking into account the patient's overall health and treatment history.